Get started
Author

Ronald Perez

Observed name: Ronald J. Pérez
ORCID: 0000-0003-3704-486X
Observed ORCID: 0000-0003-3704-486X
OpenAlex ID: A5020348364
Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium–Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis
2022 · Peter Rossing, Stefan D. Anker, et al. · Diabetes Care · 242
PDF
Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial
2023 · Katherine R Tuttle, Sibylle J Hauske, et al. · The Lancet · 228
PDF
Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes: A Mediation Analysis
2023 · Rajiv Agarwal, Wanzhu Tu, et al. · Annals of Internal Medicine · 125
Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study
2022 · Peter Rossing, Ellen Burgess, et al. · Diabetes Care · 41
PDF
Deletion of retinoic acid receptor β (RARβ) impairs pancreatic endocrine differentiation
2013 · Ronald J. Pérez, Yannick D. Benoit, et al. · Experimental Cell Research · 34
Arthralgia with risk of progression to psoriatic arthritis: role of clinical assessments and ultrasound as prognostic factors
2024 · Rodrigo Garcia-Salinas, Sebastian Magri, et al. · Rheumatology · 14
PDF
Erratum. Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study. Diabetes Care 2022;45:888–897
2023 · Peter Rossing, Ellen Burgess, et al. · Diabetes Care · 1
PDF
Impact of ACPA and RF titers and their reduction on therapeutic response after one year in rheumatoid arthritis patients
2025 · Rodrigo Garcia-Salinas, Ronald Perez, et al. · ARP Rheumatology
PDF
Works count: 8
Citation count: 685
H-index: 6
I10-index: 6
Year
Topic
Type